PLIANT THERAPEUTICS, INC.
PLIANT THERAPEUTICS, INC. (PLRX): 5 pipeline candidates · ~26 mo cash runway · 5 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
25.9 months
D/E 0.23 · 0% dilution
Lead: Phase 2
5 candidates
N/A
0 buys · 4 sells (180d)
A transparent, data-derived signal for PLIANT THERAPEUTICS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$73.7M
Cash
$23.7M
Quarterly Burn
$19.2M
Runway
25.9 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| Bexotegrast (PLN-74809) | Phase 2 |
| PLN-101095 | Phase 1 |
| PLN-101325 | Phase 1 |
| PLN-1474 | Phase 2 |
| PLN-74809 | Phase 2 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
89
Total value held
$57.2M
| Holder | Shares | Value |
|---|---|---|
| tang capital management llc | 6,143,132 | $7.7M |
| vanguard capital management llc | 4,686,202 | $5.9M |
| woodline partners lp | 3,333,660 | $4.2M |
| citadel advisors llc | 3,263,399 | $4.1M |
| adar1 capital management, llc | 2,585,126 | $3.3M |
| two sigma investments, lp | 2,253,138 | $2.8M |
| renaissance technologies llc | 1,852,842 | $2.3M |
| prosight management, lp | 1,667,600 | $2.1M |
| bml capital management, llc | 1,546,137 | $1.9M |
| peapod lane capital llc | 1,288,578 | $1.6M |
Showing top 10 of 89 institutional holders of PLIANT THERAPEUTICS, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in PLIANT THERAPEUTICS, INC.'s pipeline?
PLIANT THERAPEUTICS, INC. (PLRX) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is PLIANT THERAPEUTICS, INC.'s lead drug candidate?
PLIANT THERAPEUTICS, INC.'s most advanced tracked candidate is Bexotegrast (PLN-74809) (Phase 2) for Idiopathic Pulmonary Fibrosis; Primary Sclerosing Cholangitis.
What is PLIANT THERAPEUTICS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, PLIANT THERAPEUTICS, INC. has approximately 25.9 months of cash runway.
What is PLIANT THERAPEUTICS, INC.'s market capitalization?
PLIANT THERAPEUTICS, INC.'s market capitalization is approximately $73.7M.
Who is the CEO of PLIANT THERAPEUTICS, INC.?
Dr. Bernard Coulie M.B.A., M.D., Ph.D. is the chief executive officer of PLIANT THERAPEUTICS, INC. (PLRX).
Get the full picture on PLIANT THERAPEUTICS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.